Is NCT06526858 recruiting in Detroit, MI?

Yes, NCT06526858 is currently recruiting participants at its Detroit, MI location. This resistant hypertension clinical trial is actively enrolling qualified participants.

How do I join the resistant hypertension clinical trial in Detroit?

To join this clinical trial in Detroit, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Detroit clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Resistant Hypertension Clinical Trial in Detroit, MI

About This Resistant Hypertension Study in Detroit

HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications

Sponsor: DeepQure Inc.

Who Can Participate

Inclusion Criteria

Subjects are eligible to participate if all of the following criteria are met:

Aged ≥22 and ≤80 years old at time of enrollment (consent).

Diagnosed with resistant hypertension.

Office BP ≥140/90 mmHg at Screening Visit 1, and on at least 3 antihypertensive medications of different classes including a diuretic for at least 4 weeks prior to consent.

Daytime ABP ≥135/85 mmHg after a four (4)-week run-in period at Screening Visit 2.

Agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.

Exclusion Criteria

Subjects are not eligible to participate if any of the following criteria are met:

Has coverage diameter of renal artery less than 2 mm or greater than 11 mm.

Has one or more of the following conditions:

Unstable angina with stent implantation (percutaneous coronary intervention) within 3 months of enrolment.

Myocardial infarction within 3 months of enrollment.

Acute heart failure (New York Heart Association (NYHA) III-IV) within 3 months of enrollment

Cerebrovascular accident or transient ischemic attack within 3 months of enrollment.

Atrial fibrillation patients undergoing treatment and not in sinus rhythm. Notes: Patients who have received medical treatment, catheter or surgical treatment for atrial fibrillation and are in sinus rhythm are not excluded

Has one or more of the following confirmed anatomical findings in the kidney or renal artery that are not suitable for renal denervation (assessed by the renal CT angiography of Screening 2)

A single functioning kidney.

An atheroma, aneurysm or renal artery stent within 5 mm of the renal denervation site.

Presence of stenosis of 30% or more on all of the blood vessels available for renal denervation therapy.

When it is deemed impossible to perform denervation on both renal arteries according to the discretion of the investigator.

Has one or more of the following medical history or a history of surgery/procedure that is not suitable for renal denervation therapy

Renal denervation therapy.

Polycystic kidney disease (PKD).

Atrophic kidney.

Kidney transplant.

Dialysis due to end-stage renal disease.

Any surgery performed on both kidneys. (except endoscopy type of surgery, i.e. endoscopic kidney stone removal)

FMD (Fibromuscular dysplasia)

Has comorbidities or surgical/procedural history that are not suitable for retroperitoneal approach

Surgical history through retroperitoneal approach.

Fibrosis in the retroperitoneal region.

Inflammation in the retroperitoneal region.

Severe obesity (body mass index (BMI) \> 40 kg/m2)

Risk of increased intracranial pressure

Has a history of any intervention for underlying renal artery pathology including stenting or balloon angioplasty.

Individual has an eGFR of \<45 mL/min/1.73m2, using the 4 variable Modification of Diet in Renal Disease (MDRD) calculation (in mL/min) per 1.73 m2 = 175 x Serum Cr-1.154 x age-0.203 x 1.212 (if patient is black) x 0.742 (if female).

Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma Hb1Ac ≥ 9.0%).

Has had a reduction of SBP of ≥20 mm Hg or DBP of ≥10 mm Hg within 3 minutes of standing coupled with symptoms during the screening process (at Screening Visit 2).

Requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea (e.g., CPAP, BiPAP).

Has documented primary pulmonary hypertension.

Has an untreated secondary cause of hypertension (either known or suspected) or is taking drugs that increase sympathetic tone and could contribute to hypertension.

Has a scheduled or planned surgery that, in the opinion of the Investigator, may affect study endpoints.

Works night shifts.

Has severe cardiac valve stenosis for which, in the opinion of the Investigator, a significant reduction of blood pressure is contraindicated.

Is pregnant, nursing or planning to become pregnant during the course of the study follow-up (Note: Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to angiography).

Has a known unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable, in the opinion of the Investigator, to comply with study follow-up requirements.

Has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.

Patients who are at high risk if taken off their anticoagulant and antiplatelet agents for a few days.

Allergy, intolerance or contraindications to contrast medium.

Prescribed any standard antihypertensive cardiovascular medication for other chronic conditions (e.g. ischemic heart disease) for less than 90 days before Screening visit 1 and whose discontinuation might pose serious risk to health.

Has frequent intermittent or chronic pain that results in the treatment with non-steroidal anti-inflammatory drugs (NSAIDs) for two (2) or more days per week over the month prior to Screening Visit 2.

Concurrent enrollment in any other investigational drug or device study(Participation in non-interventional Registries is acceptable).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT06526858) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Resistant Hypertension Treatment Options in Detroit, MI

If you're searching for resistant hypertension treatment options in Detroit, MI, this clinical trial (NCT06526858) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this clinical trial. You'll receive care from experienced resistant hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all resistant hypertension clinical trials near you to find additional studies recruiting in your area.

Resistant Hypertension Clinical Trial in Detroit, MI

Expert Care in Detroit

IRB Approved

No-Cost Care

Apply for This Detroit Location

Why Participate?

Simple Process